Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia.
A cross-sectional study with internal comparison groups was conducted to describe sociodemographic characteristics, as well as verify the association between the type of antiretroviral treatment used and hyperglycemia and hyperlipidemia, with special attention to the use of HIV protease inhibitors. The data was obtained through an interview questionnaire, as well as blood and urine samples that were collected for the laboratory exams. A total of 418 patients were interviewed. 46 of these, however, met the exclusion criteria. The sample was therefore composed by 372 HIV positive patients, attended at the laboratory of the Correia Picanço State Hospital for the collection of blood, to estimate the HIV viral load and/or TCD4 cell counts from August to November 2000. The association between the variables was tested using the chi-square test and the p-value. A multiple logistic regression analysis was carried out to adjust for potential confounding factors. A greater frequency of patients with high glucose levels was observed among those making use of antiretroviral therapy without protease inhibitors, but the number of patients limited the comparisons. An association was verified between the total serum cholesterol level and the use of HIV protease inhibitors (p=0.047) even after controlling for age. An association was also observed between the triglyceride levels and the use of HIV protease inhibitors, which remained after adjustment for age, sex and creatinine levels (p<0.001). The levels of glucose and TSH, the presence of proteinuria and the practice of physical activity were not associated either with the levels of cholesterol or with the levels of tryglicerides thus they were not confounders of the associations described.
de Araújo
Paulo Sérgio Ramos
PS
Departamento de Medicina Tropical, Universidade Federal de Pernambuco, and Hospital Correia Picanço, Secretaria Estadual de Saúde de Pernambuco, Recife, PE, Brazil. psergio@elogica.com.br
de Alencar Ximenes
Ricardo Arraes
RA
Lopes
Carlos Frederico Costa
CF
Duarte
João Yure
JY
da Silva
Mecleine Mendes
MM
Carneiro
Edmilda Marques
EM
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D006949:Hyperlipidemias / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D011795:Surveys and Questionnaires
D019380:Anti-HIV Agents; D011480:Protease Inhibitors